Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q3 2023 vs. Q2 2023
How the institutions holding Revelation Biosciences, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 10 | 11 | +1 |
| Shares | 805.3K | 958.9K | +153.6K (+19.1%) |
| Value | $758.7K | $656.3K | −$102.4K (−13.5%) |
New holders (4)
Institutions that held Revelation Biosciences, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 57,360 | $39.0K | 0.00% |
| Geode Capital Management, LLC | 35,709 | $24.3K | 0.00% |
| Susquehanna International Group, LLP | 12,589 | $8.56K | 0.00% |
| UBS Group AG | 92 | $63 | 0.00% |
Sold out (3)
Institutions that held Revelation Biosciences, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Virtu Financial LLC | 66,972 | $63.0K |
| HRT Financial LP | 18,484 | $17.0K |
| Royal Bank of Canada | 100 | $0 |